X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6008) 6008
Publication (906) 906
Book Review (69) 69
Book Chapter (40) 40
Dissertation (16) 16
Conference Proceeding (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4071) 4071
humans (4005) 4005
braf (3078) 3078
oncology (2497) 2497
mutation (2447) 2447
melanoma (2142) 2142
cancer (2080) 2080
proto-oncogene proteins b-raf - genetics (1825) 1825
female (1686) 1686
male (1562) 1562
middle aged (1261) 1261
tumors (1195) 1195
genetic aspects (1113) 1113
aged (1034) 1034
adult (1031) 1031
pathology (936) 936
braf mutation (924) 924
gene mutations (916) 916
braf mutations (886) 886
metastasis (876) 876
animals (840) 840
melanoma - genetics (804) 804
cell biology (800) 800
cell line, tumor (748) 748
research (747) 747
activation (743) 743
analysis (743) 743
mutations (743) 743
colorectal cancer (732) 732
metastatic melanoma (706) 706
care and treatment (702) 702
kinases (693) 693
neoplasms (684) 684
prognosis (682) 682
vemurafenib (659) 659
expression (657) 657
melanoma - pathology (651) 651
article (649) 649
melanoma - drug therapy (632) 632
kras (591) 591
proto-oncogene proteins b-raf - metabolism (554) 554
thyroid cancer (551) 551
thyroid neoplasms - genetics (551) 551
immunohistochemistry (546) 546
aged, 80 and over (543) 543
carcinoma (534) 534
survival (516) 516
health aspects (495) 495
signal transduction (491) 491
proto-oncogene proteins b-raf - antagonists & inhibitors (478) 478
medicine & public health (477) 477
mice (468) 468
pathway (467) 467
proteins (466) 466
colorectal neoplasms - genetics (461) 461
dermatology (459) 459
chemotherapy (458) 458
biochemistry & molecular biology (450) 450
b-raf (445) 445
resistance (443) 443
antineoplastic agents - therapeutic use (435) 435
dna mutational analysis (431) 431
gene (429) 429
gene expression (425) 425
development and progression (413) 413
thyroid neoplasms - pathology (413) 413
microsatellite instability (412) 412
digestive system diseases (409) 409
apoptosis (397) 397
acquired-resistance (392) 392
skin neoplasms - genetics (387) 387
mutation - genetics (384) 384
genes (381) 381
patients (380) 380
open-label (378) 378
malignant-melanoma (372) 372
ras proteins - genetics (368) 368
skin neoplasms - pathology (367) 367
protein kinase inhibitors - pharmacology (366) 366
diagnosis (362) 362
biomarkers, tumor - genetics (361) 361
melanoma - metabolism (361) 361
inhibition (360) 360
immunotherapy (358) 358
therapy (343) 343
adolescent (339) 339
colorectal neoplasms - pathology (338) 338
cells (337) 337
young adult (334) 334
targeted therapy (332) 332
antineoplastic agents - pharmacology (323) 323
braf v600e mutation (314) 314
endocrinology & metabolism (311) 311
gene expression regulation, neoplastic (311) 311
metastases (310) 310
endocrine system diseases (309) 309
surgery (307) 307
ras (296) 296
phosphorylation (293) 293
proto-oncogene proteins - genetics (293) 293
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5969) 5969
French (35) 35
German (20) 20
Japanese (4) 4
Korean (4) 4
Polish (4) 4
Chinese (3) 3
Russian (3) 3
Spanish (3) 3
Hungarian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 10/2015, Volume 526, Issue 7574, pp. 583 - 586
Journal Article
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors
Journal Article
Journal Article
Acta Neuropathologica, ISSN 0001-6322, 6/2011, Volume 121, Issue 6, pp. 763 - 774
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 12/2011, Volume 121, Issue 12, pp. 4700 - 4711
Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine... 
MEDICINE, RESEARCH & EXPERIMENTAL | GROWTH-INHIBITION | BRAF(V600E) MUTATION | CARCINOMA CELLS | GENE | RAS | ANTISENSE RNA | KINASE | SENSITIVITY | PROLIFERATION | EXPRESSION | MAP Kinase Signaling System - physiology | Proto-Oncogene Proteins B-raf - physiology | Apoptosis - drug effects | Humans | Antineoplastic Agents - therapeutic use | Mutation, Missense | Indoles - administration & dosage | Benzamides - administration & dosage | Neoplasm Proteins - genetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Benzamides - toxicity | Diphenylamine - therapeutic use | Carcinoma, Papillary - drug therapy | Mice, Transgenic | Diphenylamine - toxicity | Sulfonamides - pharmacology | Antineoplastic Combined Chemotherapy Protocols - toxicity | Protein Kinase Inhibitors - administration & dosage | Indoles - therapeutic use | Mice | DNA Damage | Thyroid Gland - metabolism | Sulfonamides - administration & dosage | Thyroid Neoplasms - metabolism | Carcinoma, Papillary - genetics | Diphenylamine - pharmacology | Neoplasm Proteins - physiology | Carcinoma, Papillary - metabolism | Diphenylamine - analogs & derivatives | Benzamides - therapeutic use | Indoles - pharmacology | Benzamides - pharmacology | Diphenylamine - administration & dosage | Genes, Synthetic - drug effects | Indoles - toxicity | Enzyme Activation - drug effects | Iodine Radioisotopes - pharmacokinetics | Carcinoma, Papillary - pathology | Point Mutation | Thyroid Neoplasms - genetics | Animals | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Protein Kinase Inhibitors - toxicity | Sulfonamides - toxicity | Protein Kinase Inhibitors - pharmacology | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Thyroid Neoplasms - pathology | Care and treatment | Thyroid cancer | Cancer cells | Genetic aspects | Diagnosis | Properties | Isotopes | Health aspects | Mitogen-activated protein kinases | Iodine
Journal Article